Key result
Ingramon-depot reduces cardiomyocyte necrosis and myocardial fibrosis compared to placebo in diabetic mice.
Why the study?
Chronic systemic inflammation drives myocardial fibrosis in metabolic syndrome, and db/db mice model myocardial injury linked to obesity and hyperglycemia; the impact of Ingramon on inflammation and myocardial remodeling was investigated.
Does Ingramon-depot reduce inflammation and myocardial remodeling in a db/db mouse model of diabetic cardiomyopathy?
Does Ingramon-depot reduce inflammation and myocardial remodeling in a db/db mouse model of diabetic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In a db/db mouse model of diabetic cardiomyopathy, targeted antagonism of MCP-1 and IL-8 using Ingramon-depot demonstrated cardioprotective effects by reducing myocardial fibrosis and local inflammation.
Introduction. Chronic systemic inflammation is a major driver of myocardial fibrosis in patients with metabolic syndrome; accordingly, db/db mice with impaired leptin signaling are widely used to model myocardial injury associated with obesity and hyperglycemia. This study investigates the impact of the peptide Ingramon, an antagonist of MCP-1 and interleukin-8, on systemic and local inflammation and myocardial remodeling in db/db mice. Methods. Sixteen-week-old female db/db mice were assigned to an experimental group that received subcutaneous injections of Ingramon encapsulated in PLGA microcapsules (Ingramon-depot; 30 mg/kg; n = 13) once every 2 weeks for 16 weeks or to a control group that received empty microcapsules as a placebo (n = 11). Transthoracic echocardiography was performed before and after treatment. At the end of the experiment, the mice were euthanized, and blood, adipose tissue, and heart tissue samples were collected for further analysis. Results. Ingramon-depot administration was associated with changes in adipose tissue leukocyte composition. The proportions of F4/80-positive macrophages tended to be lower, and the macrophage-to-T-cell ratio was significantly reduced. Morphological analysis showed significantly less cardiomyocyte granular degeneration/coagulative necrosis and myocardial fibrosis in Ingramon-depot-treated mice. Transcriptomic analysis of the myocardium revealed lower expression of neutrophil granule genes at the gene-set level in Ingramon-depot-treated mice. Conclusion. These findings suggest that Ingramon may exert cardioprotective effects in a murine model of diabetic cardiomyopathy; the underlying mechanisms, including a possible impact on inflammatory-cell recruitment, require further investigation.
No takes yet. Share an insight, caveat, or question.
Filatova et al. (2026) studied Diabetic cardiomyopathy / Myocardial injury associated with obesity and hyperglycemia (n=24). Ingramon-depot vs. Empty microcapsules (placebo) was evaluated on Adipose tissue leukocyte composition, cardiomyocyte degeneration, and myocardial fibrosis. In a db/db mouse model, Ingramon-depot significantly reduced the macrophage-to-T-cell ratio, cardiomyocyte granular degeneration/coagulative necrosis, and myocardial fibrosis compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: